Sajith Wickramasekara

Co-founder & CEO, Benchling · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

founderexecutiveengineer@sajithw ↗LinkedIn ↗benchling.com ↗

Sajith Wickramasekara co-founded Benchling in 2012 while studying computer science at MIT, building a cloud informatics platform to replace paper lab notebooks and spreadsheets in life sciences R&D. Under his leadership, Benchling became a prominent biotech software unicorn serving hundreds of thousands of scientists across global pharmaceutical and biotechnology companies.

17statements → 7claims → 2claims resolved → 3.71/5average certainty → 1.79/5average debate potential →

2 supported 0 partly supported 0 contradicted 5 not checkable as stated how the 7 claims stand · each chip opens the sources

2 predictions · 5 assertions · 3 opinions · 4 insights · 2 disclosures · 1 what if · every statement was checked. The predictions and assertions are the 7 claims: statements the public record can support or contradict. 2 are resolved, and 5 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Sajith argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported
Wickramasekara: Biologics and advanced modalities now dominate biopharma pipelines
“Biologics, advanced modalities are now majority of the pipeline. We actually have approved cell therapies, gene therapies. We're the first gene editing medicines approved.”
Sajith Wickramasekara Dec 12, 2024 ▶ 4:14 Mastering Your Data with Sajith Wickramasekara

How they sound: speaking style how? →

276 words/min while actually speaking · 13.5 um and uh per 1k words

No argument clarity score for Sajith Wickramasekara: no usable question→answer exchanges on raw tape (a fair score needs 8+). We do not score a sample that small. Roundtable and news formats yield far fewer direct exchanges than interviews.

Measured by listening to the audio itself: 5,036 words across 2 episodes of raw-level tape, transcribed verbatim with every um and uh kept, each one attributed only where the alignment onto our timed stream is unambiguous. These are measurements of speaking style. We do not rank them: across this corpus, fluency and argument quality are nearly uncorrelated (ρ≈0.2), and smooth talking does not signal clear thinking. How it's measured →

Everything Sajith Wickramasekara said on the a16z Podcast that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Not checkable as stated
Wickramasekara: 60% of Benchling customers' laboratory instruments are unconnected
“The last time we kind of ran one of these benchmarking exercises was that For our customers, 60% of their instruments are not connected.”
Sajith Wickramasekara Dec 12, 2024 ▶ 10:31 Mastering Your Data with Sajith Wickramasekara
Insight
Wickramasekara: Vertical software markets are less competitive, risking loss of focus
“One thing actually that's probably worse about vertical companies is you, the markets are not as competitive as horizontal companies, and so you can get a little unfocused at times”
Sajith Wickramasekara Dec 12, 2024 ▶ 22:47 Mastering Your Data with Sajith Wickramasekara
Assertion Supported
Wickramasekara: Biologics and advanced modalities now dominate biopharma pipelines
“Biologics, advanced modalities are now majority of the pipeline. We actually have approved cell therapies, gene therapies. We're the first gene editing medicines approved.”
Sajith Wickramasekara Dec 12, 2024 ▶ 4:14 Mastering Your Data with Sajith Wickramasekara
Opinion
Wickramasekara: Pharma researchers do not lack tech literacy
“I think there's sometimes this, like, unfair caricature that people in pharma, like, don't know how to turn on a computer and that the industry just, like, doesn't believe in technology and so forth. I don't think belief in the technology is, like, lacking. I …”
Sajith Wickramasekara Dec 12, 2024 ▶ 5:27 Mastering Your Data with Sajith Wickramasekara
Insight
Wickramasekara: Biological research software requires highly flexible data models
“The data and the technological needs of serving biology are very, very different. You have an incredibly complex multidimensional data model that's happening while the instrumentation lab is now, you know, vastly generating more, more data than ever, ever befo…”
Sajith Wickramasekara Dec 12, 2024 ▶ 5:54 Mastering Your Data with Sajith Wickramasekara
Disclosure
Wickramasekara: Benchling has 800 employees and spends $100M annually on R&D
“We are, 800 people today. We, I think about 40% of our team works in R&D, probably spend a hundred million dollars a year on, on R&D.”
Sajith Wickramasekara Dec 12, 2024 ▶ 6:33 Mastering Your Data with Sajith Wickramasekara
Prediction Not checkable as stated
Wickramasekara: Bio AI models will 10x therapeutic molecule ideas
“I think these new bio AI models are gonna 10 X the number of really high quality ideas for therapeutic, therapeutic molecules.”
Sajith Wickramasekara Dec 12, 2024 ▶ 7:20 Mastering Your Data with Sajith Wickramasekara
Opinion
Wickramasekara: The life sciences industry is sleeping on in vivo data
“I think in vivo data is something people are sleeping on, actually.”
Sajith Wickramasekara Dec 12, 2024 ▶ 10:55 Mastering Your Data with Sajith Wickramasekara
What-if
Wickramasekara: Benchling wouldn't exist if he knew it required enterprise sales
“If you had told me when I was 21 that I was signing up to do like enterprise sales to big pharma, I'd have been like, absolutely not. I'm not starting this company.”
Sajith Wickramasekara Dec 12, 2024 ▶ 13:08 Mastering Your Data with Sajith Wickramasekara
Insight
Wickramasekara: Enterprise buyers evaluate multi-year trajectory over current capabilities
“Enterprises are not buying for the present moment. They are buying like Multi-year.”
Sajith Wickramasekara Dec 12, 2024 ▶ 17:15 Mastering Your Data with Sajith Wickramasekara
Opinion
Wickramasekara: Scaling Benchling to $1M ARR was 100x harder than scaling further
“Going from kind of zero to one was a hundred times harder than one to N.”
Sajith Wickramasekara Dec 12, 2024 ▶ 18:15 Mastering Your Data with Sajith Wickramasekara
Assertion Supported
Wickramasekara: Benchling is well past $100M in annual recurring revenue
“Well past hundred, but still very hard.”
Sajith Wickramasekara Dec 12, 2024 ▶ 19:32 Mastering Your Data with Sajith Wickramasekara
Insight
Wickramasekara: 100 deeply addicted users signal broader market demand
“If 10 people or a hundred people Were totally addicted to the software. Like that was a really good sign. Like, cause what are the chances that we found just the exact hundred people who would be completely addicted and there'd be no one else after that? So I …”
Sajith Wickramasekara Dec 2, 2021 ▶ 15:16 B2C2B in Digital Health, a founder's playbook
Assertion Not checkable as stated
Benchling failed at enterprise sales until adding business-level data features
“And actually though, at first, like we really like struck out trying to sell anything to these companies. Like scientists have used Benchling in school. They liked it, but they weren't going to buy it. The business, like the value wasn't there. And that's when…”
Sajith Wickramasekara Dec 2, 2021 ▶ 21:24 B2C2B in Digital Health, a founder's playbook
Disclosure
Benchling sells professional services with every single customer deal
“And so we heavily employ services. We sell services with every deal we do.”
Sajith Wickramasekara Dec 2, 2021 ▶ 28:48 B2C2B in Digital Health, a founder's playbook
Assertion Not checkable as stated
Wickramasekara: Benchling took a year to reach 100 daily active users
“I think it took us a year to crack a hundred active daily users.”
Sajith Wickramasekara Dec 12, 2024 ▶ 13:53 Mastering Your Data with Sajith Wickramasekara
Prediction Not checkable as stated
Wickramasekara: Benchling will eventually expand into drug manufacturing software
“We've started to get our foothold in, in development. Like, someday we'll be in parts of manufacturing.”
Sajith Wickramasekara Dec 12, 2024 ▶ 24:30 Mastering Your Data with Sajith Wickramasekara

Appearances (1)

EpisodeDateSpeaking time
Mastering Your Data with Sajith Wickramasekara Dec 12, 2024 20m

Played on the show (1)

Episodes where a recording of Sajith Wickramasekara was played rather than Sajith taking part, or where the tape carries an address with nobody putting questions to them. Listed because the words are on the record, kept out of every score on this page because they were not said on this show. We read this off the tape: who was spoken to, who was asked something, who answered whom.

EpisodeDateOn tapeWhat it is
B2C2B in Digital Health, a founder's playbook Dec 2, 2021 2m clip played
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,000 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.